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Normal Regadenoson With Normal
Adenosine Myocardial Perfusion Imaging
With Propensity Score Matching
Fahad M. Iqbal, MD,* Fadi G. Hage, MD,†‡ Ali Ahmed, MD,§ Phillip J. Dean, MD,¶
Saleem Raslan, MD,† Jaekyeong Heo, MD,† Ami E. Iskandrian, MD†
New Orleans, Louisiana; and Birmingham, Alabama
O B J E C T I V E S The aim of this study was to test the hypothesis that patients with normal
regadenoson myocardial perfusion imaging (MPI) have a low rate of cardiac events, similar to patients
with normal adenosine MPI.
B A C KG ROUND Regadenoson, a new selective adenosine A2A receptor agonist, is now a widely
used stress agent for MPI. The low rate of cardiac events in patients with normal adenosine MPI is
well-documented, but the prognostic implications of a normal regadenoson MPI have not been
examined and compared with those with adenosine.
METHOD S Data on primary composite endpoint (cardiac death, myocardial infarction, and coronary
revascularization) were collected for 2,000 patients (1,000 regadenoson, and 1,000 adenosine stress) with
normal myocardial perfusion and left ventricular ejection fraction referred for vasodilator MPI. In
addition, propensity scores were used to assemble a balanced cohort of 505 pairs of patients who were
balanced on 36 baseline characteristics.
R E S U L T S The primary endpoint occurred in 21 (2.1%; 1.1%/year) patients in the regadenoson group
and 33 (3.3%; 1.7%/year) patients in the adenosine group (hazard ratio [HR] for regadenoson vs.
adenosine: 0.62; 95% conﬁdence interval [CI]: 0.36 to 1.08; p  0.090). In the propensity-matched pairs,
the primary endpoint occurred in 7 (1.4%; 0.7%/year) patients in the regadenoson group and 13 (2.6%;
1.3%/year) patients in the adenosine group (matched HR: 0.58; 95% CI: 0.23 to 1.48; p  0.257). Cardiac
deaths were infrequent in the entire sample and in the propensity-matched groups; the cardiac death
rate was 0.9%/year and 1.15%/year in the regadenoson and adenosine groups (HR: 0.77; 95% CI: 0.42 to
1.43; p  0.404) in the pre-match sample and 0.5%/year and 0.7%/year in the matched groups,
respectively (HR: 0.83; 95% CI: 0.25 to 2.73; p  0.763).
CONC L U S I O N S Major cardiac events are infrequent in patients with normal regadenoson MPI.
These ﬁndings provide assurance that normal MPI using a simpler stress protocol with regadenoson
provides prognostic data similar to normal adenosine MPI. (J Am Coll Cardiol Img 2012;5:1014–21)
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1015T
he role of myocardial perfusion imaging
(MPI) in risk stratification of patients is well-
established, both with exercise and with vaso-
dilator stress (1–8). Up to 50% of MPI studies
re performed in the United States with vasodilator
tress, traditionally with adenosine or dipyridamole
9–11). Adenosine produces coronary hyperemia
ut is a nonselective stress agent, because it stimu-
ates multiple receptor subtypes. A meta-analysis by
avare et al. (1) demonstrated that patients with
ormal adenosine MPI have a low rate of future
ardiac events, 1% to 2% annually.
See page 1022
Regadenoson is a selective adenosine A2A receptor
agonist and is now the stress agent most widely used in
the United States, despite the short time since its ap-
proval by the Food and Drug Administration (FDA).
Unlike adenosine, regadenoson is given as a bolus rather
than as an infusion, simplifying the testing protocol, and
is better-tolerated by patients (12–14). Although ran-
domized phase 3 multicenter trials have demonstrated
that regadenoson is noninferior to adenosine for the
detection of reversible perfusion abnormalities (15,16),
there are no data on risk prediction, especially the
prognostic value of normal regadenoson MPI. This
information is needed, because of the concern that
normal images might be falsely normal, because regade-
noson is given as a bolus rather than as infusion and
therefore the timing of tracer injection in relation to the
bolus injection is crucial to the image results. Unlike
adenosine, regadenoson is given as a fixed dose that is not
adjusted for weight, raising concerns for suboptimal
dosing in overweight individuals. Furthermore, it is
inherently important to perform prognostic studies with
new stress agents to confirm the implications of using
these agents in practice, because the prognostic data are
of more relevance to the clinician than the diagnostic
data.
The objective of the current study is to compare
outcomes of patients with normal regadenoson and
adenosine MPI. Considering the diagnostic equiva-
lence of these 2 agents, we hypothesized that patients
with normal regadenoson MPI will have similar prog-
nosis to patients with normal adenosine MPI.
M E T H O D S
Study population. Data were collected on 2,000
patients who had normal vasodilator-only MPI. Of
these, 1,000 consecutive patients had normal re-
gadenoson MPI performed between July 2008 and tJune 2009, and another 1,000 consecutive patients
had normal adenosine MPI performed between July
2006 and June 2007 (before our center switched
from adenosine to regadenoson). All patients had
normal left ventricular ejection fraction (LVEF).
The institutional review board for human research
at the University of Alabama at Birmingham ap-
proved this study.
MPI. Adenosine was administered intravenously as an
nfusion (140 g/kg/min for 5 min). Technetium-
99m-sestamibi was injected at 3 min into the infusion.
Regadenoson was administered as a single peripheral
intravenous bolus of 0.4 mg, followed by saline flush.
Technetium-99m-sestamibi was administered intra-
venously, 10 to 20 s after the saline flush. All the
studies were done in the absence of accompanying
exercise.
Gated single-photon emission computed tomog-
raphy images were acquired 1 h after tracer injection
with a dual-head detector gamma camera
with a low-energy, high-resolution colli-
mator with a 64 64 matrix. The cameras
operated in an elliptical 180° acquisition
orbit with 32 projections and 30 s/projec-
tion. A 15% energy window centered on
the 140-keV gamma peak was used for
imaging. Gating was done with 8 to 16
frames/RR cycle. Butterworth filtering
followed by filtered back projection recon-
struction was performed, and image inter-
pretation was done without attenuation or
scatter correction. All MPI were inter-
preted by readers blinded to subsequent
events. Rest images were obtained when-
ever there was uncertainty in the interpretation of
the stress images as previously described (17). The
images were interpreted visually and aided by auto-
mated polar maps with the 4DM program (18–20).
The LVEF and end-diastolic and end-systolic vol-
umes were measured from stress gated images on
the basis of a method previously described by
Germano et al. (21). For purposes of this study,
normal MPI was defined as LVEF 50% and
normal perfusion pattern.
Other baseline characteristics. Variables abstracted
rom the medical records of patients included pa-
ient demographic data; comorbidities including
rior myocardial infarction (MI), diabetes mellitus,
ypertension, hyperlipidemia, and stroke; prior car-
iovascular interventions, such as percutaneous cor-
nary intervention or coronary artery bypass graft-
ng; history of tobacco use; medication usage at the
A B B
A N D
CI c
eGFR
filtrat
HR
LVEF
fractio
MACE
cardio
MI
MPI
imagiime of MPI; and laboratory results (serumR E V I A T I O N S
A C R O N YM S
onfidence interval
 estimated glomerular
ion rate
hazard ratio
 left ventricular ejection
n
major adverse
vascular event
myocardial infarction
myocardial perfusioncreati-
e
m
s
c
y
d
c
a
t
o
i
m
i
S
2
c
r
b
d
e
a
v
P
s
s
c
s
g
a
s
p
m
v
F
m
r
g
A
q
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 0 , 2 0 1 2
O C T O B E R 2 0 1 2 : 1 0 1 4 – 2 1
Iqbal et al.
Prognostic Value of Normal Regadenoson MPI
1016nine and lipid panel). The estimated glomerular
filtration rate (eGFR) was calculated according to
the Modification of Diet in Renal Disease study
formula (22). Patients were considered to have
chronic kidney disease if their eGFR was 15 to 60
ml/min/1.73 m2. Patients were considered to have
nd-stage renal disease if their eGFR was 15
l/min/1.73 m2 or if they were receiving renal
replacement therapy.
Outcomes variables. The primary outcome of the
tudy is a composite endpoint of major adverse
ardiovascular events (MACE) occurring within 2
ears of the normal MPI. These include cardiac
eath, nonfatal MI (as documented by appropriate
ombination of symptoms, electrocardiography,
nd enzyme changes), and coronary revasculariza-
ion with either percutaneous coronary intervention
r coronary artery bypass grafting. Cardiac mortal-
ty is defined as death resulting from fatal arrhyth-
ias, MI, or heart failure as determined by review-
ng electronic medical records and verified with
ocial Security Death Index database up to June 13,
011. Cardiac catheterization and coronary revas-
ularization data were verified by review of hospital
Pre-match
Post-match
0
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Inpatient testing
Transplant evaluation
Chest pain
Prior MI
HR response
Aldactone
Resting diastolic BP
Serum Creatinine
Prior PCI
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Former smoker
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Pre-operative
Metformin
Figure 1. Love Plot of Selected Variables
Absolute standardized differences before and after propensity score
blood pressure; CABG  coronary artery bypass grafting; CCB  ca
kidney disease; CVA  cerebrovascular accident; FRS  Framingham
MI  myocardial infarction; PCI  percutaneous coronary intervent
attack.ecords. Time to event is defined as days from
aseline to first MACE event, noncardiovascular
eath, or end of 2 years of follow-up. Secondary
ndpoints are cardiac and all-cause mortality.
Assembly of a balanced study cohort. Baseline char-
cteristics of patients with normal regadenoson
ersus normal adenosine MPI were compared with
earson chi-square, Student t, or Wilcoxon rank
um tests as appropriate (23). Considering the
ignificant differences in distribution of key baseline
haracteristics between the groups, we used propen-
ity scores to assemble a cohort in which the 2
roups are balanced on all measured baseline char-
cteristics. We began by estimating propensity
cores for the receipt of regadenoson with a non-
arsimonious logistic regression model (24). In the
odel, receipt of regadenoson was the dependent
ariable, and baseline characteristics displayed in
igure 1 were entered as covariates. With a “greedy”
atching protocol; we matched patients in the
egadenoson group with those in the adenosine
roup who had similar propensity scores (24).
bsolute standardized differences that directly
uantify bias in the means (or proportions) of
20 30 40 50 60 70 80 90
olute Standardized Difference (%)
tching for patients receiving regadenoson versus adenosine. BP 
channel blocker; CHF  congestive heart failure; CKD  chronic
sk Score; HR  heart rate; LVEF  left ventricular ejection fraction;
PVD  peripheral vascular disease; TIA  transient ischemic10
bs
ma
lcium
Ri
ion;
m
p
a
e
i
o
t
u
m
o
r
n
y
p
c
f
p
v
A
v
2
w
a
a
s
B
h
0
e
i
h
(
5
p
f
r
a
t
s
9
a
s
p
m
(
g
v
0
c
t
r
s
9
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 0 , 2 0 1 2
O C T O B E R 2 0 1 2 : 1 0 1 4 – 2 1
Iqbal et al.
Prognostic Value of Normal Regadenoson MPI
1017covariates across the treatment groups were esti-
mated, and findings were expressed as a percentage
of pooled SDs were presented as Love plots (25).
Statistical analysis. Baseline characteristics of
atched patients were compared with McNemar,
aired t, and Wilcoxon rank sum tests, as appropri-
te. Cox proportional hazards models were used to
stimate hazard ratios (HRs) and 95% confidence
ntervals (CIs), comparing primary and secondary
utcomes in the regadenoson group with those in
he adenosine group. A conditional Cox model was
sed to estimate the HR for the propensity score-
atched pairs. In consideration of the low number
f events, a separate multivariable-adjusted Cox
egression model adjusting for the 36 covariates was
ot attempted. Instead, we repeated our initial anal-
sis in the 2,000 pre-match participants, adjusting for
ropensity scores. Event-free survival curves were
onstructed with the Kaplan-Meier method, and dif-
erences were estimated by the log-rank test for the
re-match groups. All tests were 2-tailed, and a p
alue 0.05 was considered statistically significant.
ll statistical analyses were carried out with PASW
ersion 18 (SPSS, Inc., Chicago, Illinois).
R E S U L T S
Baseline characteristics. Overall, patients (n 
,000) had an age of 59  12 years; 55% were
omen, and 35% were African Americans. Imbal-
nces in baseline characteristics before matching
nd balances achieved after matching between the 2
tudy groups are displayed in Table 1 and Figure 1.
efore matching, patients in the regadenoson group
ad a higher proportion of men (47% vs. 43%, p 
.04) and more tests ordered for pre-transplant
valuations (41% vs. 19%, p  0.001) than patients
n the adenosine group. The regadenoson group
ad fewer patients with prior coronary interventions
14% vs. 17%, p  0.06), hyperlipidemia (45% vs.
1%, p 0.03), and history of prior MI (5% vs. 9%,
 0.001) than the adenosine group. Medication
use was similar between the groups, except that
more patients in the regadenoson group were re-
ceiving calcium channel blockers (31% vs. 26%, p
0.02) and potassium sparing diuretics (11% vs. 7%,
p  0.002) (Online Table 1). After matching, only
transplant evaluation as an indication for MPI
maintained an imbalance, occurring more often in
the regadenoson group (5% vs. 2%, p  0.07).
Primary outcomes. Among the 2,000 pre-match pa-
tients, the primary endpoint (cardiac death, MI,
and coronary revascularization) occurred in 21(2.1%; 1.1%/year) and 33 (3.3%; 1.7%/year) pa-
tients in the regadenoson and adenosine groups,
respectively (HR for regadenoson: 0.62; 95% CI:
0.36 to 1.08; p  0.09) (Table 2), during a mean
ollow-up of 22  5 months (23  4 months for
egadenoson; 22  5 months for adenosine). After
djustment for propensity score in the entire cohort,
here was no significant difference associated with
tress agent used (propensity-adjusted HR: 0.63;
5% CI: 0.32 to 1.22; p  0.169). Kaplan-Meier
nalysis with MACE as the endpoint was not
tatistically different between the groups (log-rank
 0.087) (Fig. 2). In the propensity score-
atched pairs, MACE occurred in 7 (1.4%) and 13
2.6%) patients in the regadenoson and adenosine
roups, respectively (matched HR for regadenoson
s. adenosine: 0.58; 95% CI: 0.23 to 1.48; p 
.257) (Table 3). This association remained un-
hanged after additional adjustment for transplan-
ation as an indication for MPI, because this was a
emaining unbalanced covariate in the matched
ample (transplant indication-adjusted HR: 0.55;
5% CI: 0.22 to 1.38; p  0.201).
Other outcomes. Overall, 236 patients died during 2
years of follow-up after index MPI. Common
causes of noncardiac death were cancer and sepsis.
Among the 2,000 pre-match patients, cardiac death
occurred in 18 (1.8%; 0.9%/year) and 23 (2.3%;
1.15%/year) patients in the regadenoson and aden-
osine groups, respectively (HR: 0.77; 95% CI: 0.42
to 1.43; p  0.404) (Table 2). These associations
remained unchanged after adjustment for propen-
sity score (propensity-adjusted HR: 0.88; 95% CI:
0.42 to 1.86; p  0.736).
Among the 2,000 pre-match patients, a combi-
nation of cardiac death and nonfatal MI occurred in
18 (1.8%; 0.9%/year) and 25 (2.5%; 1.25%/year)
patients in the regadenoson and adenosine groups,
respectively (HR: 0.71; 95% CI: 0.39 to 1.30; p 
0.261). These associations remained unchanged
after adjustment for propensity score (propensity-
adjusted HR: 0.80; 95% CI: 0.38 to 1.66; p 
0.547).
In the propensity score-matched pairs, cardiac
death occurred in 5 (1.0%) and 7 (1.4%) matched
patients in the regadenoson and adenosine groups,
respectively (matched HR: 0.83; 95% CI: 0.25 to
2.73; p  0.763) (Table 3). These associations
remained unchanged after additional adjustment for
transplantation as an indication for MPI (transplant
indication-adjusted HR: 0.72; 95% CI: 0.23 to
2.28; p  0.576).
A
a
peripheral vascular disease
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1018After 2 years of follow-up from the index MPI in
the 2,000 pre-match patients, there were 106 deaths
(5.3%/year) in the regadenoson group and 130
racteristics by Stress Agent Before and After Propensity Score M
Before Propensity Score Matching
Adenosine (n  1,000) Regadenoson (n  1,000) p Va
60 12 59 12 0.2
426 (43) 474 (47) 0.0
0.5
646 (65) 624 (62)
339 (34) 357 (36)
15 (2) 19 (2)
786 (79) 773 (77) 0.5
505 (51) 454 (45) 0.0
378 (38) 358 (36) 0.4
288 (29) 245 (25) 0.0
72 (7) 62 (6) 0.4
162 (16) 180 (18) 0.3
239 (24) 242 (24) 0.9
88 (9) 45 (5) 0.0
134 (13) 97 (10) 0.0
66 (7) 65 (7) 1.0
11 4 11 4 0.1
260 (26) 278 (28) 0.4
177 (18) 185 (19) 0.6
386 (39) 43 (4) 0.0
72 13 72 13 0.9
132 21 132 22 0.8
74 11 75 11 0.0
29 21 32 20 0.0
67 10 67 9 0.3
2.46 3.00 2.83 3.31 0.0
59 34 58 39 0.6
518 (52) 405 (41) 0.0
n 186 (19) 408 (41) 0.0
39 (4) 47 (5) 0.4
257 (26) 140 (14) 0.0
n (%).
G  coronary artery bypass grafting; CAD  coronary artery disease; CHF  cong
RS  Framingham risk score; GFR  glomerular ﬁltration rate; LV  left ventricu
; TIA  transient ischemic attack.
Table 2. Association Between Stress Agent Used and Outcomes
the 2,000 Patients
Events, % (n)
Abso
Differe
Regadenoson
(n  1,000)
Adenosine
(n  1,000)
MACE 2.1 (21) 3.3 (33) 1
Cardiac mortality 1.8 (18) 2.3 (23) 0
All-cause mortality 10.6 (106) 13 (130) 2CI  conﬁdence interval; HR  hazard ratio; MACE  major adverse cardiac events.(6.5%/year) in the adenosine group (p  0.091).
fter propensity score matching, there were 52
ll-cause deaths (5.15%/year) in the regadenoson
ing
After Propensity Score Matching
Adenosine (n  505) Regadenoson (n  505) p Value
61 12 61 12 0.9
201 (40) 206 (41) 0.9
0.8
336 (67) 344 (68)
164 (33) 156 (31)
5 (1) 5 (1)
365 (72) 368 (73) 0.9
246 (49) 241 (48) 0.9
163 (32) 163 (32) 0.9
130 (26) 127 (25) 0.9
29 (6) 31 (6) 0.9
88 (17) 85 (17) 0.9
136 (27) 130 (26) 0.8
33 (7) 35 (7) 0.9
71 (14) 72 (14) 1.0
40 (8) 31 (6) 0.3
12 4 12 4 0.2
130 (26) 140 (28) 0.6
100 (20) 105 (21) 0.8
56 (11) 43 (9) 0.2
72 13 72 14 0.9
131 20 130 22 0.6
75 10 75 11 0.9
33 22 32 19 0.2
68 9 68 9 0.6
1.55 1.97 1.71 2.30 0.2
70 28 71 35 0.9
330 (65) 348 (69) 0.5
24 (5) 12 (2) 0.07
29 (6) 37 (7) 0.4
122 (24) 108 (21) 0.4
e heart failure; CKD  chronic kidney disease; CVA  cerebrovascular accident;
I  myocardial infarction; PCI  percutaneous coronary intervention; PVD 
ong
, % Unadjusted HR (95% CI)
Propensity-Adjusted HR*
(95% CI)
0.62 (0.36–1.08); p  0.090 0.63 (0.32–1.22); p  0.169
0.77 (0.42–1.43); p  0.404 0.88 (0.42–1.86); p  0.736
0.80 (0.62–1.04); p  0.091 0.73 (0.53–1.00); p  0.048Table 1. Baseline Cha atch
lue
Age
Male 4
Race
White
Black
Other
Hypertension
Hyperlipidemia 3
DM
CKD 3
CHF
PVD/CVA/TIA
CAD
Prior MI 01
Prior PCI 1
Prior CABG
FRS
Former smoker
Current smoker
Inpatient testing 01
Testing parameters
Resting heart rate
Resting systolic BP
Resting diastolic BP 02
Heart rate response 01
LV ejection fraction
Serum creatinine 09
Estimated GFR
Indication for testing
Chest pain/dyspnea 001
Transplant evaluatio 001
Pre-operative
Other 001
Values are mean  SD or
BP  blood pressure; CAB estiv
DM  diabetes mellitus; F lar; MAm
lute
nce
.2
.5
.4
*Additional adjustment for propensity score.
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1019group and 64 (6.35%/year) in the adenosine group
(p  0.122) (Table 3).
Side effects. Side effects occurred significantly more
requently in the adenosine group at the time of
esting. Chest pain dyspnea and bronchospasm
ere the most common adverse effects (Online
able 2).
D I S C U S S I O N
The findings of the current study demonstrate that
patients with normal regadenoson MPI (normal
perfusion and LVEF) have low incident cardiovas-
cular events during a 2-year follow-up that did not
exceed those encountered with adenosine. There is
no statistically significant difference in these events
in a cohort of propensity-matched patients. To the
best of our knowledge, this is the first study of the
prognostic value of normal regadenoson MPI.
These findings are important, because they suggest
that a normal regadenoson MPI is as effective as a
normal adenosine MPI in identifying patients at
low risk of MACE (defined here as cardiac death,
nonfatal MI, and coronary revascularization).
The unadjusted near-significant lower MACE in
the regadenoson group is likely due to confounding
by selection bias. Patients in the regadenoson group
were younger and had fewer cardiovascular risk
factors such as hyperlipidemia, renal insufficiency,
and prior MI. These patients were less likely to be
referred due to chest pain and more likely to be
referred for pre-transplant evaluation. However,
when adjusted for imbalances in baseline character-
istics, in a propensity-matched cohort as well as
adjusting for propensity scores in the original co-
hort, there was no significant difference in the
primary endpoint, suggesting no independent asso-
ciation between regadenoson and cardiac outcomes.
Importantly, there was no significant difference in
cardiac mortality between the 2 groups. It should be
emphasized that, before matching, the events rates
were lower and not higher in the regadenoson
group. This is an important observation, because
our concern was that the bolus method of injection
might conceal true abnormalities and hence in-
crease the rate of false negative scans. The fact that
with or without matching, the event rates were not
higher in the regadenoson group is therefore quite
assuring.
Regadenoson is a selective adenosine A2A recep-
or agonist and has much lower affinity for non-A2A
adenosine receptor subtypes, which are believed to
be associated with adverse effects attributed tononselective agonists such as adenosine. Coronary
vasodilation is a physiological response that has a
very large A2A receptor reserve (26). Regadenoson
s given intravenously as a bolus at a dose of 0.4 mg
ith no weight adjustment, simplifying administra-
ion and mitigating errors in dose calculations.
egadenoson induces peak hyperemia that starts
ithin 30 s of injection and lasts 2 to 3 min
27–29). The A2A receptor prevalence in the heart,
its importance to coronary vasodilation, and the
rapid onset and peak of action of regadenoson allow
it to be given as a bolus but still provide adequate
vasodilation for stress MPI.
Since its approval by the FDA in 2008, regade-
noson has become the most commonly used vaso-
dilator stress agent with MPI. In the United States,
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Figure 2. Kaplan-Meier Curves for Major Adverse Cardiovascula
Kaplan-Meier curves for major adverse cardiovascular events in 1,00
mal regadenoson MPI versus 1,000 with normal adenosine myocard
ing. There is no difference in major adverse cardiovascular events a
vasodilator received during imaging during 2 years of follow-up.
Table 3. Association Between Stress Agent Used and Outcomes
the 1,010 Propensity-Matched Patients
Events, % (n)
Absolute
Difference, % Ma
Regadenoson
(n  505)
Adenosine
(n  505)
MACE 1.4 (7) 2.6 (13) 1.2 0.58 (
Cardiac mortality 1.0 (5) 1.4 (7) 0.4 0.83 (
All-cause mortality 10.3 (52) 12.7 (64) 2.4 0.74 (= 0.087
ine
enoson
2422
r Events
0 patients with nor-
ial perfusion imag-
ccording to theAmong
tched HR (95% CI)
0.23–1.48); p  0.257
0.25–2.73); p  0.763
0.50–1.08); p  0.122Abbreviations as in Table 2.
T
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1020as of February 2011, regadenoson is used in 68%,
adenosine in 15%, and dipyridamole in 13% of
vasodilator MPI (the remaining studies use dobut-
amine) (29). The FDA approval of regadenoson
was based on results of the ADVANCE MPI
(Adenosine versus Regadenoson Comparative
Evaluation for Myocardial Perfusion Imaging) trials
(15,16,30), which demonstrated no clinical differ-
ences in efficacy or safety between adenosine and
regadenoson in a wide spectrum of patients (30).
The concordance between regadenoson and
adenosine was better by automated (polar maps)
than by visual analysis (number of reversible
defects) (16). The ADVANCE MPI trials did
not provide prognostic data on the regadenoson
MPI, although there is a large body of evidence
in support of the prognostic usefulness of aden-
osine MPI (6 – 8,31,32).
Adenosine MPI has been well-accepted in risk
stratification of many patient groups, and therefore
it is imperative that any new stress agent not only
have similar diagnostic accuracy but also confers the
same prognostic information. In the current era of
healthcare reform and cost-saving measures, appro-
priate application of testing and post-test manage-
ment requires knowledge of the value of a test after
consideration of the other clinical and historical
factors that are known to the physician at the time
of testing (8,33). With this approach, the statistical
and clinical incremental value for adenosine single-
photon emission computed tomography MPI has
been demonstrated (4,8,33,34). The current study
extends these findings to regadenoson MPI as
shown by several models used in our analysis inberry CD, Wasserleben V, Cave V. men. Impact of diPrior studies suggest that patients undergoing
vasodilator MPI are, as a group, at a higher risk for
future MACE than those undergoing exercise MPI
and that the event rate in patients with a normal
adenosine MPI is higher than patients with normal
exercise MPI, reflecting the differences in baseline
risk (5). The outcome of patients who received
adenosine in our study is consistent with previously
reported data (1,6). The use of all-cause mortality in
some of the earlier studies might explain the
higher-than-expected event rates in patients with
normal adenosine images (3,5,32). Regadenoson
was associated with fewer adverse effects, compared
with adenosine in our population and is, in general,
better-tolerated by patients (12,13,15,30).
Study limitations. The results were obtained in a
single tertiary care academic institution and might
not be generalizable, and the findings need to be
replicated in other patient populations. The study
was not randomized. However, we used propensity
scores to assemble a cohort in which the 2 groups
were balanced on most key baseline confounders.
Despite the large sample size, these results should
be considered exploratory in nature. Finally, we did
not examine the prognostic value of abnormal MPI,
which needs to be addressed in future studies.
C O N C L U S I O N S
The 2-year incidence of MACE is low in patients
with normal regadenoson MPI and does not exceed
that seen in patients with normal adenosine MPI.
Reprint requests and correspondence: Dr. Fahad M. Iqbal,
ulane University Heart and Vascular Institute, 1430
ulane Avenue, SL-48, New Orleans, Louisiana 70112.which the results were independent of stress agent. E-mail: fiqbal1@tulane.edu.R E F E R E N C E S
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